Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
85 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Tetanus - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Tetanus - Pipeline Review, H2 2014', provides an overview of the Tetanus's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Tetanus - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tetanus and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tetanus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Tetanus pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Tetanus - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Tetanus pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Tetanus Overview 9 Therapeutics Development 10 Pipeline Products for Tetanus - Overview 10 Pipeline Products for Tetanus - Comparative Analysis 11 Tetanus - Therapeutics under Development by Companies 12 Tetanus - Therapeutics under Investigation by Universities/Institutes 14 Tetanus - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Tetanus - Products under Development by Companies 19 Tetanus - Products under Investigation by Universities/Institutes 20 Tetanus - Companies Involved in Therapeutics Development 21 Sanofi 21 GlaxoSmithKline plc 22 Daiichi Sankyo Company, Limited 23 Takeda Pharmaceutical Company Limited 24 Biological E. Limited 25 Novartis AG 26 Zydus Cadila Healthcare Limited 27 Green Cross Corporation 28 LG Life Sciences, Ltd. 29 Bharat Biotech International Limited 30 Sinovac Biotech Ltd. 31 Serum Institute of India Limited 32 Indian Immunologicals Limited 33 Beijing Minhai Biotechnology Co., Ltd 34 Sanofi Pasteur SA 35 Tetanus - Therapeutics Assessment 36 Assessment by Monotherapy Products 36 Assessment by Combination Products 37 Assessment by Target 38 Assessment by Route of Administration 40 Assessment by Molecule Type 42 Drug Profiles 44 diphtheria + tetanus toxoids + acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine adsorbed - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 DtwP-HB-Hib (liq) Vaccine - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis (inactivated) + haemophilus influenza polysaccharide conjugate [serogroup B] vaccine - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 GC-1107 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 DTwP-HBV-Hib - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 VN-0103 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Hexavalent DTwP-Hepb-Hib-IPV Vaccine - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Pentavalent DTwP-Hib-IPV Vaccine - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 GSK-217744 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 TAK-361S - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 diphtheria + tetanus+ pertussis vaccine - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 diphtheria + pertussis + tetanus vaccine - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 diphtheria + pertussis + tetanus vaccine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Tetanus Vaccine - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Toxoid Vaccine for Diptheria and Tetanus - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Vaccine for Diptheria, Tetanus and Pertussis - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Diptheria Tetanus Pertussis And Haemophilus Type B Conjugate Vaccine - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 GC-3111A - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 DTwP-IPV - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 DTaP Vaccine - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Diphtheria + Tetanus + Pertussis (Acellular) Vaccine - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 DPT-H-HiB Vaccine - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Tetanus Vaccine - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 tetanus vaccine - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 DTwP-Hep B-IPV-Hib - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 DTwP-IPV + Hib - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 DTwP + Hib - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Tetanus - Recent Pipeline Updates 75 Tetanus - Dormant Projects 76 Tetanus - Product Development Milestones 77 Featured News & Press Releases 77 Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age 77 Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima 77 Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine 78 Nov 02, 2012: GSK Announces Voluntary Recall Of Infanrix Hexa Due To Potential Contamination 79 Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 79 Oct 11, 2012: GSK Announces Voluntary Recall Of Six Batches Of Infanrix Hexa In Australia 80 Jun 22, 2012: Sanofi Pasteur's Hexaxim Receives Positive Opinion From European Medicines Agency 80 Nov 16, 2011: Quadrivalent Vaccine TAK-361S Enters Into Phase II Clinical Trials In Japan 81 Jul 30, 2010: Sanofi Pasteur to acquire all shares of Joint Venture with Daiichi-Sankyo in Japan 82 Nov 10, 2008: Sanofi Pasteur First International Vaccine Company to Enter Japan with Pediatric vaccine 83 Appendix 84 Methodology 84 Coverage 84 Secondary Research 84 Primary Research 84 Expert Panel Validation 84 Contact Us 85 Disclaimer 85
List of Tables Number of Products under Development for Tetanus, H2 2014 10 Number of Products under Development for Tetanus - Comparative Analysis, H2 2014 11 Number of Products under Development by Companies, H2 2014 13 Number of Products under Investigation by Universities/Institutes, H2 2014 14 Comparative Analysis by Late Stage Development, H2 2014 15 Comparative Analysis by Clinical Stage Development, H2 2014 16 Comparative Analysis by Early Stage Development, H2 2014 17 Comparative Analysis by Unknown Stage Development, H2 2014 18 Products under Development by Companies, H2 2014 19 Products under Investigation by Universities/Institutes, H2 2014 20 Tetanus - Pipeline by Sanofi, H2 2014 21 Tetanus - Pipeline by GlaxoSmithKline plc, H2 2014 22 Tetanus - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 23 Tetanus - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 24 Tetanus - Pipeline by Biological E. Limited, H2 2014 25 Tetanus - Pipeline by Novartis AG, H2 2014 26 Tetanus - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 27 Tetanus - Pipeline by Green Cross Corporation, H2 2014 28 Tetanus - Pipeline by LG Life Sciences, Ltd., H2 2014 29 Tetanus - Pipeline by Bharat Biotech International Limited, H2 2014 30 Tetanus - Pipeline by Sinovac Biotech Ltd., H2 2014 31 Tetanus - Pipeline by Serum Institute of India Limited, H2 2014 32 Tetanus - Pipeline by Indian Immunologicals Limited, H2 2014 33 Tetanus - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2014 34 Tetanus - Pipeline by Sanofi Pasteur SA, H2 2014 35 Assessment by Monotherapy Products, H2 2014 36 Assessment by Combination Products, H2 2014 37 Number of Products by Stage and Target, H2 2014 39 Number of Products by Stage and Route of Administration, H2 2014 41 Number of Products by Stage and Molecule Type, H2 2014 43 Tetanus Therapeutics - Recent Pipeline Updates, H2 2014 75 Tetanus - Dormant Projects, H2 2014 76
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
